Evofem Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share data)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Product sales, net | $18,218 | $16,837 |
| Operating expenses: | ||
| Cost of goods sold | 6,512 | 4,415 |
| Research and development | 2,939 | 25,032 |
| Selling and marketing | 11,664 | 43,951 |
| General and administrative | 14,950 | 27,563 |
| Total operating expenses | 36,065 | 100,961 |
| Loss from operations | (17,847) | (84,124) |
| Other income (expense): | ||
| Interest income | 31 | 85 |
| Other expense, net | (2,628) | (2,087) |
| Loss on issuance of financial instruments | (6,776) | (72,993) |
| Gain (loss) on debt extinguishment | 75,337 | (24,487) |
| Change in fair value of financial instruments | 4,879 | 106,952 |
| Total other income, net | 70,843 | 7,470 |
| Income (loss) before income tax | 52,996 | (76,654) |
| Income tax expense | (17) | (44) |
| Net income (loss) | 52,979 | (76,698) |
| Deemed dividends | (2,984) | (1,316) |
| Net income (loss) attributable to common stockholders | $49,995 | $(78,014) |
| Net income (loss) per share attributable to common stockholders: | ||
| Basic (Note 2) | $10.36 | $(167.42) |
| Diluted (Note 2) | $0.05 | $(167.42) |
| Weighted-average shares used to compute net income (loss) per share: | ||
| Basic | 4,826,763 | 465,967 |
| Diluted | 984,038,574 | 465,967 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.